Navigation Links
Oncology Therapeutics Market in India to 2018 Report
Date:8/9/2013

DUBLIN, Ireland, August 9, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/lxh575/oncology) has announced the addition of the "Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

GBI Research, the leading business intelligence provider, has released its latest research, ""Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players"", which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin's Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pipeline.

The Indian oncology therapeutics market for breast cancer, lung cancer, colorectal cancer, prostate cancer and NHL was estimated to be worth $153.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 12.7% from 2004. It is expected to reach $238.8m in 2018 at a CAGR of 6.5% from 2011. The slower growth in the forecast period is mainly due to the reduction in the price of leading marketed products for breast cancer, colorectal cancer, lung cancer and NHL after all 348 drugs on the National List of Essential Medicines (NLEM) are brought under price control regulations.

The limitations of the current market are unclear patent laws, restrictive pricing and reimbursement policies, ailing infrastructure, and insufficient go
'/>"/>

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
2. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
5. ReachMD Adds ‘Oncology Power Hour’ to Weekly Line Up, Delivering Expert Opinions and Medical Interviews to On Air, Online, and Mobile Learners
6. Project Oncology CME Series Launches on ReachMD, Offering Learners a Wide Array of Certified Oncology Activities Across an Integrated Platform
7. Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
8. Predictive Biomarker Discovery for Oncology Small-Molecules and Biologics - a Webinar Hosted by Xtalks
9. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
10. Prova Education Hires Oncology Expert Alana Brody to Further Expand its Oncology Education and Opportunities
11. Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... WALTHAM, Mass., Nov. 2, 2010 Repligen Corporation (Nasdaq: ... second quarter of fiscal year 2011, ended September 30, ... compared to total revenue of $5,421,000 for the second ... or 35%.  Bioprocessing product revenue for the second quarter ...
... Inc. (OTC Bulletin Board: WDST ), a ... therapies to restore the health of damaged tissues and ... newest advancements in regenerative medicine on November 9th, 2010 ... role in the commercialization of the therapeutic candidate, PermaDerm™, ...
... of a Nobel prize this year but research led ... Warwick has found molecular hooks on the surface of ... provide massive benefits to researchers using transmission electron microscopes. ... mechanisms. The research team, which includes Drs. Jeremy Sloan, ...
Cached Biology Technology:Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 2Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 3Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 4Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 5Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 6Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 7Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine 2Pivoting hooks of graphene's chemical cousin could revolutionize work of electron microscopes 2
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... in their blood are more likely to survive the disease, ... of vitamin D have half the risk of dying compared ... The study is the first to correlate total blood levels ... which includes that produced after exposure to sunlight and ... survival prospects. , The University of Edinburgh team tested ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
Breaking Biology News(10 mins):The impact of big data on health care: Health Affairs' July issue 2
... of great whales ever recorded? To answer that ... the Wildlife Conservation Society have joined experts from other ... Commission on the Patagonian coast of Argentina to try ... issue is the long-term conservation of the southern right ...
... "Four and 20 black birds baked in a pie" but ... analysis, means scientists now know there is one more species of ... thought. And if Dr. Gary Voelker has his way, he,ll soon ... deforestation now occurring across its native habitat. The bird ...
... resistance to sea lice treatments such as the pyrethroids ... Pyrethroid use still increased from 2008 to 2009, although ... are being used again due to resistance problems, e.g. ... been used since 1997, was also used again in ...
Cached Biology News:Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3African bird discovery proves there is something new under the sun 2
Request Info...
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
Request Info...
... E. coli containing a clone of the human ... Topoisomerase II alters the topological state of nucleic ... a transient break which generates a separate DNA ... double-stranded DNA passage mechanism, the enzyme can relax ...
Biology Products: